DexCom Inc. (DXCM)

DexCom is a medical-device company that makes continuous glucose monitoring systems, or CGMs. These are small wearable sensors that sit on a person’s body and measure glucose (blood sugar) levels in real time, sending readings to a smartphone. For people with diabetes, especially those who take insulin, a CGM is transformative: instead of testing blood sugar with finger pricks four to ten times a day, they get readings every five minutes and can set alarms for dangerous highs and lows. DexCom’s G7 system has become the leading CGM in the U.S. market, and the company is now expanding into Europe and building a broader ecosystem of products and software that embed glucose monitoring into everyday health management.

The CGM market: from niche to mainstream

Diabetes affects over 100 million people globally, and type 1 diabetes (the form requiring insulin injections) has historically been managed with multiple daily finger-stick tests and insulin shots. This regimen is burdensome, imprecise, and leaves room for dangerous mistakes. Continuous glucose monitors were originally invented to address this, but for decades they were expensive, finicky, and used only by people with severe disease. DexCom, founded in 1997, was one of the early entrants, but the company nearly went bankrupt multiple times as it fought to improve the sensor technology and win insurance reimbursement.

The turning point came in the mid-2010s. As DexCom’s sensors became smaller, more accurate, and more durable, and as insurance companies increasingly covered CGMs, the market shifted. Suddenly, a once-niche device became something hundreds of thousands of people could access and wanted to use. Type 2 diabetes (managed without insulin by many patients) also saw growing CGM adoption as people realized that even small glucose improvements mattered for long-term health. DexCom’s revenue accelerated from millions a year to billions, and the company’s profitability followed.

Today, CGMs are still a fraction of the diabetes-management market globally, but growth rates are in the 20–30 percent range annually, far outpacing the growth of the diabetes population itself. This is a market-share story: more diabetics are switching from finger-stick testing to CGMs, and DexCom has been winning that migration.

How DexCom makes money

The company’s revenue comes from several sources. The largest is sensor sales: a person with diabetes buys a new DexCom sensor every 10–14 days, and the company either sells it directly or it goes through health insurance. Insurance pays DexCom a wholesale price, and the patient pays a copay. Over a year, a person might buy 26 sensors. When multiplied across hundreds of thousands of users, that is substantial recurring revenue. Unlike a drug that a person takes once and is done with, a CGM sensor is consumable and must be replaced constantly. This creates a recurring revenue stream and switching costs: once a patient is comfortable with DexCom’s sensor and software, switching to a competitor means learning a new system and adapting to different accuracy or usability.

The company also earns money from software and data services. A person with a CGM generates dozens of data points every day, and DexCom’s apps analyze that data, provide insights, and send alerts. DexCom has begun licensing its glucose data and algorithms to other health platforms and device makers, creating a second revenue stream from intellectual property and partnerships. Pharma companies studying new diabetes drugs also contract with DexCom to use glucose data, which provides additional revenue with minimal marginal cost.

The business model is capital-efficient: once a manufacturing plant is built, DexCom can scale production without proportional increases in cost. This is the hallmark of a software-like business embedded in a hardware device.

Competitive intensity and moat

DexCom faces real competition. Medtronic, one of the world’s largest medical-device companies, also makes CGMs and has insurance relationships and hospital distribution channels that DexCom lacks. Abbott (which acquired the Freestyle Libre brand) is another strong competitor. A handful of private companies are also pursuing CGM technology. The market is growing fast enough that all these players can win, but DexCom’s lead is real: its sensor is generally considered more accurate and faster to warm up than competitors’, and its user interface is considered more intuitive. That translates to better adherence (people who start using DexCom tend to stick with it) and higher patient satisfaction.

The moat is not unassailable, though. If a competitor launches a sensor that is materially more accurate or durable, or if insurance coverage shifts dramatically in favor of another brand, DexCom’s position could erode. The company’s lead is based on superior engineering and user experience, not on a patent that will last forever or a government-granted monopoly. It must keep innovating to stay ahead.

Growth drivers and headwinds

DexCom’s near-term growth is powered by market penetration: more people with diabetes adopting CGMs instead of finger sticks. Longer term, growth depends on expanding into type 2 diabetes (most diabetes cases), international markets, and non-diabetes uses where glucose monitoring might matter (such as general wellness for non-diabetics).

The main headwind is reimbursement. Insurance companies decide whether to cover CGMs and how much they will pay. If a major insurer restricts coverage, DexCom’s growth could slow. Regulatory approval also matters: expanding the CGM indication to new populations or new geographies requires clinical trials and government sign-off. These are slow processes.

There is also the threat of price competition. As the CGM market matures and grows, margins may compress as insurers push back on pricing or new entrants undercut DexCom on cost. The company’s ability to maintain pricing power depends on keeping its sensors better than the competition’s and on sustaining insurance coverage as the standard of care.

Capital returns and reinvestment

DexCom reinvests most of its earnings into R&D and international expansion. The company has not historically paid dividends or done large buybacks; instead, it grows by reinvesting and acquiring smaller companies or technologies that strengthen its position. This is consistent with a growth-stage medical-device company that sees significant runway ahead. Shareholders are betting that this reinvestment will compound over years and deliver returns through share price appreciation rather than dividends.

Understanding DexCom’s value

The 10-K filing (SEC CIK 0001093557) lays out revenue by geography and customer segment, explains reimbursement trends, and describes competitive threats. Earnings calls reveal growth rates in key markets, insurance coverage updates, and any progress on new indications or international launches.

Key metrics to watch include the number of active users (people using a DexCom sensor), retention rate (what fraction keep using it), and average revenue per user (how much DexCom makes from each person). Gross margin indicates whether pricing power is holding or eroding. R&D spending shows management’s commitment to maintaining its competitive edge.

DexCom is best understood as a medical-device company in a growing market with a leading position and strong tailwinds from increasing diabetes prevalence and the shift toward continuous monitoring. The stock trades on growth expectations; near-term earnings are secondary to whether the company can keep winning market share, maintain insurance coverage, and expand into new indications. For investors, this is a bet that DexCom’s innovation moat is real and that the glucose-monitoring market will grow for at least another decade.